PMID- 12429626
OWN - NLM
STAT- MEDLINE
DCOM- 20030616
LR  - 20201212
IS  - 1078-0432 (Print)
IS  - 1078-0432 (Linking)
VI  - 8
IP  - 11
DP  - 2002 Nov
TI  - Dendritic cells pulsed with HER-2/neu-derived peptides can induce specific T-cell 
      responses in patients with gastric cancer.
PG  - 3394-400
AB  - PURPOSE: We have previously reported (K. Kono et al., Int. J. Cancer, 78: 
      202-208, 1998) that HER-2/neu-derived peptides are naturally processed as 
      tumor-associated antigens recognized by tumor-specific, human leukocyte antigen 
      (HLA)-A2-restricted CTLs in gastric cancer. In the present study, we described a 
      Phase-1 vaccination trial in gastric cancer patients using dendritic cells (DCs) 
      pulsed with the immunodominant HER-2/neu(p369) peptides. EXPERIMENTAL DESIGN: 
      Nine enrolled patients, who had HER-2/neu-overexpressing tumors and who were 
      HLA-A2 positive, received four vaccinations by DCs pulsed with HER-2(p369) 
      peptide at 2-week intervals intradermally. RESULTS: There were no serious adverse 
      effects noted in the immunized patients. Peripheral blood mononuclear cells, 
      preimmunization and after the fourth immunization, were cultured with autologous, 
      HER-2(p369)-pulsed antigen-presenting cells for 12 days. Thereafter, peptide 
      specificity was evaluated by IFN-gamma secretion assay from cultured T cells 
      against T2 cells pulsed with HER-2(p369) peptide. HER-2/neu peptide-specific 
      recognition could be demonstrated in six of nine patients after immunization, 
      whereas there was no HER-2/neu peptide-specific recognition before immunization. 
      The peptide-specific CTL lines isolated from two of the patients could also lyse 
      a HER2/neu-transfected cell line. Furthermore, a peptide-specific delayed-type 
      hypersensitivity response occurred in three of nine patients. One of the patients 
      underwent a partial clinical response concurrent with a decrease of tumor marker. 
      Another patient demonstrated a stabilization of disease status for a period of 3 
      months. CONCLUSIONS: Taken together, tumor vaccination therapy with DCs pulsed 
      with HER-2/neu-peptides may be a potential candidate for the novel treatment of 
      gastric cancer patients.
FAU - Kono, Koji
AU  - Kono K
AD  - First Department of Surgery, Yamanashi Medical University, Yamanashi, 409-3898 
      Japan. kojikono@res.yamanashi-med.ac.jp
FAU - Takahashi, Akihiro
AU  - Takahashi A
FAU - Sugai, Hidemitsu
AU  - Sugai H
FAU - Fujii, Hideki
AU  - Fujii H
FAU - Choudhury, A Raja
AU  - Choudhury AR
FAU - Kiessling, Rolf
AU  - Kiessling R
FAU - Matsumoto, Yoshiro
AU  - Matsumoto Y
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Clin Cancer Res
JT  - Clinical cancer research : an official journal of the American Association for 
      Cancer Research
JID - 9502500
RN  - 0 (CA-19-9 Antigen)
RN  - 0 (Cancer Vaccines)
RN  - 0 (Carcinoembryonic Antigen)
RN  - 0 (Epitopes)
RN  - 0 (HLA-A2 Antigen)
RN  - 0 (Peptides)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - Adult
MH  - Aged
MH  - CA-19-9 Antigen/blood
MH  - Cancer Vaccines
MH  - Carcinoembryonic Antigen/blood
MH  - Dendritic Cells/*metabolism
MH  - Epitopes
MH  - HLA-A2 Antigen/biosynthesis
MH  - Humans
MH  - Immunohistochemistry
MH  - Leukocytes, Mononuclear/metabolism
MH  - Male
MH  - Middle Aged
MH  - Peptides/chemistry/*therapeutic use
MH  - Receptor, ErbB-2/*therapeutic use
MH  - Stomach Neoplasms/*therapy
MH  - T-Lymphocytes/*metabolism
MH  - Time Factors
MH  - Transfection
EDAT- 2002/11/14 04:00
MHDA- 2003/06/17 05:00
CRDT- 2002/11/14 04:00
PHST- 2002/11/14 04:00 [pubmed]
PHST- 2003/06/17 05:00 [medline]
PHST- 2002/11/14 04:00 [entrez]
PST - ppublish
SO  - Clin Cancer Res. 2002 Nov;8(11):3394-400.